{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"3"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"}]}],"title":"CEBPA (CCAAT/enhancer-binding protein alpha)"},{"categories":[{"measurements":[{"groupId":"OG001","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"title":"DNMT3A (DNA [cytosine-5]-methyltransferase 3A)"},{"categories":[{"measurements":[{"groupId":"OG001","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"}]}],"title":"FLT3 (Fms-like tyrosine kinase 3)"},{"categories":[{"measurements":[{"groupId":"OG001","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}],"title":"FLT3-ITD (FLT3 internal tandem duplications)"},{"categories":[{"measurements":[{"groupId":"OG001","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"title":"IDH1 (Isocitrate dehydrogenase 1)"},{"categories":[{"measurements":[{"groupId":"OG001","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"}]}],"title":"IDH2 (Isocitrate dehydrogenase 2)"},{"categories":[{"measurements":[{"groupId":"OG001","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"title":"KIT(Tyrosine-protein kinase Kit)"},{"categories":[{"measurements":[{"groupId":"OG001","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"title":"KRAS(Kirsten rat sarcoma 2 viral oncogene homolog)"},{"categories":[{"measurements":[{"groupId":"OG001","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"0"}]}],"title":"NPM1 (Nucleophosmin)"},{"categories":[{"measurements":[{"groupId":"OG001","value":"5"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}],"title":"NRAS(Neuroblastoma RAS viral oncogene homolog)"},{"categories":[{"measurements":[{"groupId":"OG001","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}],"title":"RUNX1 (Runt related transcription factor 1)"},{"categories":[{"measurements":[{"groupId":"OG001","value":"3"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}],"title":"TET2 (Tet methylcytosine dioxygenase 2)"},{"categories":[{"measurements":[{"groupId":"OG001","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"title":"WT1 (Wilm's tumour tumor suppressor gene1)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"1"}],"units":"Participants"}],"description":"Peripheral blood and bone marrow aspirate were collected for baseline mutational analyses. Genetic abnormalities frequently associated with AML were analyzed. These genetic abnormalities included known mutations in the genes NPM1, CEBPA, FLT3, RUNX1, IDH1, IDH2, KIT, K Ras, N Ras and WT1. Additional genes with mutations known to be associated with AML and MDS such as TET2 and DNMT3A were also evaluated.","groups":[{"description":"AML participants who achieved CR, CRi, MLFS, PR, or PRi (AML investigator reported best overall response), and MDS participants who achieved CR, mCR, PR, or SD (MDS investigator reported best overall response).","id":"OG000","title":"Phase 1B: Glasdegib + LDAC (Biomarker, Responder)"},{"description":"AML subjects who did not achieve CR, CRi, MLFS, PR, or PRi; and MDS subjects who did not achieve CR, mCR, PR or SD were defined as non-responders for best overall response.","id":"OG001","title":"Phase 1B: Glasdegib + LDAC (Biomarker, Non-Responder)"},{"description":"AML participants who achieved CR, CRi, MLFS, PR, or PRi (AML investigator reported best overall response), and MDS participants who achieved CR, mCR, PR, or SD (MDS investigator reported best overall response).","id":"OG002","title":"Phase 1B: Glasdegib + Decitabine (Biomarker,Responder)"},{"description":"AML participants who did not achieve CR, CRi, MLFS, PR, or PRi; and MDS participants who did not achieve CR, mCR, PR or SD were defined as non-responders for best overall response.","id":"OG003","title":"Phase 1B: Glasdegib + Decitabine (Biomaker,Non-Responder)"},{"description":"AML subjects who achieved CR, CRi, MLFS, PR, or PRi (AML investigator reported best overall response), and MDS subjects who achieved CR, mCR, PR, or SD (MDS investigator reported best overall response). Dauno is short for daunorubicin.","id":"OG004","title":"Phase 1B: Glasdegib + Cytarabine/Dauno (Biomarker, Responder)"},{"description":"AML participants who did not achieve CR, CRi, MLFS, PR, or PRi; and MDS participants who did not achieve CR, mCR, PR or SD were defined as non-responders for best overall response. Dauno is short for daunorubicin.","id":"OG005","title":"Phase 1B: Glasdegib+Cytarabine/Dauno(Biomarker,Non-Responder)"}],"paramType":"NUMBER","populationDescription":"Pharmacodynamic (PD) analysis set: all enrolled participants in the Phase 1B portion who received at least 1 dose of glasdegib; responders and non-responders in each arm with at least 1 PD parameter from the corresponding assay sample with a baseline and an adequate post treatment assessment.","reportingStatus":"POSTED","timeFrame":"Baseline (Cycle 1/Day 1 pre-dose for Glasdegib + LDAC and Glasdegib + Decitabine Arms; Induction Cycle 1/Day -3 pre-dose for Glasdegib +Cytarabine/Daunorubicin Arm)","title":"Number of Participants With Disease-related Gene Mutations at Phase 1B","type":"SECONDARY","unitOfMeasure":"Participants"}